Evidence map›Paper›PMID 30032392›Full record

Observational studyInternational journal of hematology2018

Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.

Jun Nakashima, Yoshitaka Imaizumi, Hiroaki Taniguchi, Koji Ando, Masako Iwanaga, Hidehiro Itonaga, Shinya Sato, Yasuhi Sawayama, Tomoko Hata, Shinichiro Yoshida and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jun NakashimaAtomic Bomb Disease and Hibakusha Medicine Unit, Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. y-imaizm@nagasaki-u.ac.jp.
Hiroaki TaniguchiDepartment of Hematology, Sasebo City General Medical Center, Nagasaki, Japan.
Koji AndoAtomic Bomb Disease and Hibakusha Medicine Unit, Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masako IwanagaDepartment of Frontier Life Science, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Hidehiro ItonagaDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Shinya SatoDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Yasuhi SawayamaDepartment of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Tomoko HataAtomic Bomb Disease and Hibakusha Medicine Unit, Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Shinichiro YoshidaDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Medical Center, Nagasaki, Japan.
Yasushi MiyazakiAtomic Bomb Disease and Hibakusha Medicine Unit, Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia-lymphoma (ATL) is a distinct T-cell malignancy caused by human T-cell leukemia virus type-1; the prognosis is very poor. Mogamulizumab (Moga), an antibody drug for CC chemokine receptor type 4, has been introduced for the treatment of ATL. However, the prognosis of relapsed or refractory ATL remains poor and the characteristics of patients who derive clinical benefit from treatment with Moga remain poorly understood. We analyzed the associations of clinical factors with the outcome after Moga treatment. Forty-five patients treated with Moga monotherapy were evaluated. The median age of the patients was 69 years, and 40% were female. The median overall survival (OS) time was 17.6 months and the 2-year OS rate was 43.2%. Number of prior therapies and response to prior therapy were predictive clinical features in univariate analysis for OS. Performance status, corrected serum calcium level, serum lactate dehydrogenase level, Japan Clinical Oncology Group-prognostic index (PI), and simplified ATL-PI at Moga treatment were also associated with the prognosis after Moga monotherapy. Improved understanding of the clinical factors predicting the prognosis after Moga may contribute to improved treatment strategies for ATL.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedDisease-Free SurvivalFemaleHumansLeukemia-Lymphoma, Adult T-CellMaleMiddle AgedRisk FactorsSurvival RateAntibodies, Monoclonal, HumanizedmogamulizumabATLMogamulizumabPrognostic factors

Identifiers

PMID30032392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.